A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

ClinicalTrials.gov ID: NCT05131022

Public ClinicalTrials.gov record NCT05131022. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Study identification

NCT ID: NCT05131022
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Enrollment: 572 participants

Conditions and interventions

Conditions

Interventions

NX-5948 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 12, 2022
Primary completion: Dec 31, 2026
Completion: Dec 31, 2027
Last update posted: Apr 13, 2026

2022 – 2028

United States locations

U.S. sites: 18
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
University of California, San Francisco	San Francisco	California	94143	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
University of Miami	Miami	Florida	33136	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Winship Cancer Institute of Emory University	Atlanta	Georgia	30322	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
National Institute of Health	Bethesda	Maryland	20814	Recruiting
Cayuga Medical Center	Ithaca	New York	14850	Withdrawn
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Active, not recruiting
Duke University Medical Center	Durham	North Carolina	27705	Recruiting
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19104	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Withdrawn
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 44 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05131022, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05131022 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →